Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-20

Study Completion Date

2017-08-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled.

Safety, efficacy, and PK assessments occurred at scheduled visits over a 12-week period. Low-molecular-weight non-steroidal immunosuppressive medications were allowed up to the baseline day as long as the dose had not changed in the 3 weeks prior to baseline, except for corticosteroid doses for which might have changed.

Patients responding to treatment were offered up to 6 months of extended treatment. Assessments for safety included laboratory safety tests, ECGs, physical exams, ocular exams, vital signs and the monitoring of adverse events. Study participation varied from a minimum of 3 months to a maximum of 9 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of AIN457 in Noninfectious Uveitis

NCT00685399

Non-infectious Uveitis

COMPLETED PHASE2

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

NCT01747538

Uveitis

TERMINATED PHASE3

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01032915

Non-infectious Uveitis

TERMINATED PHASE3

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis

NCT01684345

Uveitis

TERMINATED PHASE3

A Clinical Trial of Infliximab for Uveitis

NCT00273390

Uveitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 24 patients with active non-infectious uveitis, in at least one eye, requiring intensification of systemic immunosuppressive therapy were enrolled and randomized to receive intravitreal LFG316 or conventional therapy (investigator's discretion). Only one eye (the study eye) were treated with LFG316 and the other eye (fellow eye) were treated at the investigator's discretion.Throughout the study, the fellow eye might have been treated as needed; except that certain systemic medications were prohibited. There was 1 screening and 8 scheduled visits over 85 days for a total of 9 site visits for all patients.

At Day 85, patients receiving LFG316 treatment who met the criteria for a 'responder', were offered an additional 6 months of LFG316 treatment on a PRN basis. Additional 3 scheduled visits were attended by LFG316-responder patients during the extension period. However, patients could have unscheduled visits as needed and as determined by the investigator. Safety evaluation and ocular assessments were performed throughout the study duration. Patients in the treatment extension phase, who experienced a flare post their last dose and required treatment, might have received a dose of LFG316. These patients were assessed for a response at their next PRN visit as scheduled by the investigator. Visit frequency was determined by the investigator. If they continued to respond to LFG316 therapy, they might have remained in the PRN treatment arm. They might have received up to 7 additional doses of LFG316 in the PRN period. Throughout the trial LFG316 were not administered more frequently than monthly. Patients in the extension phase, who discontinued treatment prematurely were asked to return approximately 1 month after their last dose. Low molecular weight non-steroidal immunosuppressive medications were allowed up to the baseline day as long as the dose had not changed in the 3 weeks prior to baseline, except for corticosteroid doses which might have changed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-infectious Intermediate Uveitis Non-infectious Posterior Uveitis Non-infectious Panuveitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LFG316 -Intravitreal Injection

Group Type EXPERIMENTAL

LFG316

Intervention Type DRUG

LFG316 administered intravitreally (IVT)

Conventional Therapy

Group Type ACTIVE_COMPARATOR

Conventional Therapy

Intervention Type DRUG

Conventional Therapy administered in accordance with its prescribing info.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LFG316

LFG316 administered intravitreally (IVT)

Intervention Type DRUG

Conventional Therapy

Conventional Therapy administered in accordance with its prescribing info.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients 18 years or older
* Active NIU, in at least one eye, as defined below, in patients requiring intensification of systemic immunosuppressive therapy;
* Vitreous haze at least 1+ on the scale of Nussenblatt et al 1985,or
* Chorioretinal lesions due to uveitis (chorioretinal lesions due to infectious uveitis excluded)
* Patients with a flare and at the time of the enrollment on systemic corticosteroid or non-steroidal immunosuppressants had their therapy tapered or stopped, respectively, at the time of intravitreal LFG316 administration.

Visual acuity (ETDRS method) of 20 letters (20/400 Snellen equivalent) or better in the study eye.

* For female patients, must not be pregnant or lactating and must, unless post-menopausal, use effective contraception.
* Ability to provide informed consent and comply with the protocol.

Exclusion Criteria

* Uveitis so severe that, in the investigator's judgment, it was too risky to test an experimental drug
* Any biologic immunosuppressive agent given via intravitreal, intravenous or subcutaneous route within 4-12 months depending on the agent.
* History of infectious uveitis or endophthalmitis in either eye.
* History of retinal detachment
* Any intraocular surgery, intravitreal injection, periocular injection, or laser photocoagulation to the study eye within 90 days prior to dosing.
* In the study eye, cataract expected to interfere with study conduct or require surgery during the study.
* Forms of uveitis that may have spontaneously resolved

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No